Matches in SemOpenAlex for { <https://semopenalex.org/work/W2518883927> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2518883927 endingPage "e15511" @default.
- W2518883927 startingPage "e15511" @default.
- W2518883927 abstract "e15511 Background: To determine if AS EOC pts evaluated by gynecologic oncologists at one institution and believed not to be surgically cytoreducible (SC) to ≤ 1 cm diameter of residual disease (RD) had a significantly different PFS and OS with NACT (CP) followed by cytoreductive surgery compared to (AS) EOC pts believed to be SC to ≤ 1 cm RD with USC followed by CP. Methods: 221 USC pts (stage IIIC-169, IV-52) and 95 NACT pts (stage III-40, IV-55) treated between 1996 and 2009 were retrospectively reviewed. NACT pts received a median of 6 cycles of C (AUC 6) and P (175 mg/M2) prior to surgery. All NACT pts had imaging findings compatible with AS nonoptimally SC EOC and pathology consistent with EOC. Kaplan-Meier curves were performed for survival analyses. A student T-test was used to compare clinical variables. Results: The PFS and OS for Stage IIIC NACT pts (median 32.5 mos. and 47.5 mos. respectively) was not statistically different than USC pts (median 19.5 and 45.7 mos. respectively; p = 0.099 and 0.918 respectively). The PFS and OS for stage IV NACT pts (median 15.6 and 25.8 mos. respectively) was not statistically different than USC pts (median 13.0 and 48.5 mos.) (p = 0.841and 0.701 respectively). Pts who had no RD at the completion of their initial surgery (NACT 72.8%, USC 43.8%) had statistically improved OS and PFS compared to those with residual tumor. Stage IIIC NACT pts had significantly less postoperative hospital days (5.9 vs. 8.5), blood loss (487 vs. 909 cc) and transfusions (0.6 vs. 1.4) than USC pts. Stage IV NACT pts+ had significantly less hospital days (7.3 vs. 9.8) and blood loss at surgery (413 vs 689) than USC pts. Conclusions: NACT is an appropriate option for AS EOC pts who appear to be non-optimally SC with upfront surgery. No significant financial relationships to disclose." @default.
- W2518883927 created "2016-09-23" @default.
- W2518883927 creator A5002826928 @default.
- W2518883927 creator A5006775642 @default.
- W2518883927 creator A5008166734 @default.
- W2518883927 creator A5010339370 @default.
- W2518883927 creator A5018914509 @default.
- W2518883927 creator A5022101888 @default.
- W2518883927 creator A5026827320 @default.
- W2518883927 date "2010-05-20" @default.
- W2518883927 modified "2023-09-28" @default.
- W2518883927 title "Neoadjuvant carboplatin and paclitaxel (CP) chemotherapy (NACT) in patients (pts) with advancedstage (AS) epithelial ovarian cancer (EOC) compared with upfront surgical cytoreduction (USC) followed by CP." @default.
- W2518883927 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e15511" @default.
- W2518883927 hasPublicationYear "2010" @default.
- W2518883927 type Work @default.
- W2518883927 sameAs 2518883927 @default.
- W2518883927 citedByCount "0" @default.
- W2518883927 crossrefType "journal-article" @default.
- W2518883927 hasAuthorship W2518883927A5002826928 @default.
- W2518883927 hasAuthorship W2518883927A5006775642 @default.
- W2518883927 hasAuthorship W2518883927A5008166734 @default.
- W2518883927 hasAuthorship W2518883927A5010339370 @default.
- W2518883927 hasAuthorship W2518883927A5018914509 @default.
- W2518883927 hasAuthorship W2518883927A5022101888 @default.
- W2518883927 hasAuthorship W2518883927A5026827320 @default.
- W2518883927 hasConcept C121608353 @default.
- W2518883927 hasConcept C126322002 @default.
- W2518883927 hasConcept C141071460 @default.
- W2518883927 hasConcept C143998085 @default.
- W2518883927 hasConcept C146357865 @default.
- W2518883927 hasConcept C151730666 @default.
- W2518883927 hasConcept C2776694085 @default.
- W2518883927 hasConcept C2778239845 @default.
- W2518883927 hasConcept C2780427987 @default.
- W2518883927 hasConcept C2781451048 @default.
- W2518883927 hasConcept C2989005 @default.
- W2518883927 hasConcept C71924100 @default.
- W2518883927 hasConcept C86803240 @default.
- W2518883927 hasConcept C90924648 @default.
- W2518883927 hasConceptScore W2518883927C121608353 @default.
- W2518883927 hasConceptScore W2518883927C126322002 @default.
- W2518883927 hasConceptScore W2518883927C141071460 @default.
- W2518883927 hasConceptScore W2518883927C143998085 @default.
- W2518883927 hasConceptScore W2518883927C146357865 @default.
- W2518883927 hasConceptScore W2518883927C151730666 @default.
- W2518883927 hasConceptScore W2518883927C2776694085 @default.
- W2518883927 hasConceptScore W2518883927C2778239845 @default.
- W2518883927 hasConceptScore W2518883927C2780427987 @default.
- W2518883927 hasConceptScore W2518883927C2781451048 @default.
- W2518883927 hasConceptScore W2518883927C2989005 @default.
- W2518883927 hasConceptScore W2518883927C71924100 @default.
- W2518883927 hasConceptScore W2518883927C86803240 @default.
- W2518883927 hasConceptScore W2518883927C90924648 @default.
- W2518883927 hasIssue "15_suppl" @default.
- W2518883927 hasLocation W25188839271 @default.
- W2518883927 hasOpenAccess W2518883927 @default.
- W2518883927 hasPrimaryLocation W25188839271 @default.
- W2518883927 hasRelatedWork W1567229547 @default.
- W2518883927 hasRelatedWork W1967715255 @default.
- W2518883927 hasRelatedWork W2060767396 @default.
- W2518883927 hasRelatedWork W2072767112 @default.
- W2518883927 hasRelatedWork W2105623825 @default.
- W2518883927 hasRelatedWork W2123388967 @default.
- W2518883927 hasRelatedWork W2311734504 @default.
- W2518883927 hasRelatedWork W2330726202 @default.
- W2518883927 hasRelatedWork W2410995755 @default.
- W2518883927 hasRelatedWork W2968124559 @default.
- W2518883927 hasVolume "28" @default.
- W2518883927 isParatext "false" @default.
- W2518883927 isRetracted "false" @default.
- W2518883927 magId "2518883927" @default.
- W2518883927 workType "article" @default.